Invion

Invion OCF Growth YoY

The Year-over-Year Operating Cash Flow Growth of Invion (IVX.AX) as of Oct 19, 2026 is 20.05 %. In the previous year, Year-over-Year Operating Cash Flow Growth was -23.63 % — a change of -184.85% (higher).

OCF Growth YoY

20.05 %

YoY

-184.85%

Last updated:

Year-over-Year Operating Cash Flow Growth of Invion is 2026 20.05 % . Year-over-Year Operating Cash Flow Growth of Invion was 2025 -23.63 % . It decreases by -184.85% higher compared to the previous year.

The Invion OCF Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Growth YoY
Date
OCF Growth YoY
Jan 1, 2019
-397.80 AUD
Jan 1, 2020
92.76 AUD
Jan 1, 2021
374.14 AUD
Jan 1, 2022
-365.30 AUD
Jan 1, 2023
-63.47 AUD
Jan 1, 2024
-32.47 AUD
Jan 1, 2025
-23.63 AUD
Jan 1, 2026
20.05 AUD
The Invion OCF Growth YoY history
YEAROCF Growth YoYYoY
20.05 %-184.85%
-23.63 %-27.23%
-32.47 %-48.83%
-63.47 %-82.63%
-365.30 %-197.64%
374.14 %+303.34%
92.76 %-123.32%
-397.80 %-203.03%
386.11 %+312.73%
93.55 %+50.46%
62.17 %-146.86%
-132.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Year-over-Year Operating Cash Flow Growth of Invion is 20.05 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Operating Cash Flow Growth Invion since 2006 – with annual values, charts, and detailed analysis.

OCF growth measures the percentage change in operating cash flow. Growing OCF indicates improving cash generation from core operations.

To evaluate Year-over-Year Operating Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Operating Cash Flow Growth.

Year-over-Year Operating Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Operating Cash Flow Growth's Invion historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Invion

All Key Metrics — Invion